Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 3,000 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Elena Ridloff sold 3,000 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $87.00, for a total transaction of $261,000.00. Following the completion of the sale, the director owned 3,000 shares in the company, valued at approximately $261,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Elena Ridloff also recently made the following trade(s):

• On Tuesday, March 31st, Elena Ridloff sold 7,400 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.37, for a total value of $631,738.00.
• On Wednesday, April 1st, Elena Ridloff sold 4,600 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.42, for a total value of $392,932.00.

Kymera Therapeutics Stock Down 2.3%

Kymera Therapeutics stock traded down $1.98 during mid-day trading on Monday, hitting $84.10. 467,535 shares of the company were exchanged, compared to its average volume of 691,637. The business has a fifty day moving average of $84.25 and a 200 day moving average of $76.97. Kymera Therapeutics, Inc. has a 1-year low of $28.06 and a 1-year high of $103.00. The company has a market capitalization of $6.92 billion, a PE ratio of -23.56 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. The company had revenue of $34.37 million for the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.82) earnings per share. Research analysts expect that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC boosted its stake in shares of Kymera Therapeutics by 169.1% during the 4th quarter. SG Americas Securities LLC now owns 22,693 shares of the company’s stock worth $1,766,000 after acquiring an additional 14,261 shares during the period. Hudson Bay Capital Management LP boosted its stake in shares of Kymera Therapeutics by 362.7% during the 3rd quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company’s stock worth $1,309,000 after acquiring an additional 18,134 shares during the period. Federated Hermes Inc. bought a new position in shares of Kymera Therapeutics during the 3rd quarter worth approximately $31,622,000. Candriam S.C.A. boosted its stake in shares of Kymera Therapeutics by 24.4% during the 3rd quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock worth $10,847,000 after acquiring an additional 37,536 shares during the period. Finally, Knights of Columbus Asset Advisors LLC bought a new position in shares of Kymera Therapeutics during the 3rd quarter worth approximately $1,069,000.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on KYMR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Jefferies Financial Group started coverage on Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 price target on the stock. Citigroup lifted their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Royal Bank Of Canada reissued an “outperform” rating and issued a $108.00 target price on shares of Kymera Therapeutics in a research report on Thursday, February 26th. Finally, Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $118.10.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.